IART INTEGRA LIFESCIENCES HOLDINGS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 917520 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.8%
TTM net income YoY102.6%
TTM EPS YoY102.6%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-49.5%
Margins
Gross margin52.4%
Operating margin4.4%
Net margin0.8%
FCF margin5.2%
EBITDA margin—
Returns
ROE1.2%
ROA0.4%
ROIC (approx.)2.8%
Asset turnover0.46x
Leverage & solvency
Liabilities / assets69.6%
Debt / equity0.65x
Current ratio3.62x
Interest coverage0.79x
Cash quality & payout
Operating cash flow / net income10.79x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Cost of revenue | $803.62M | $728.47M | $656.84M | $587.36M | $597.81M |
| Gross profit | $831.62M | $882.06M | $884.74M | $970.31M | $944.64M |
| R&D expense | $98.97M | $115.38M | $104.19M | $101.19M | $93.05M |
| SG&A expense | $699.70M | $716.98M | $656.64M | $616.32M | $637.45M |
| Operating income | -$493.37M | $28.41M | $111.53M | $238.92M | $197.23M |
| Interest expense | $86.25M | $70.63M | $51.38M | $49.59M | $50.40M |
| Pretax income | -$563.50M | -$18.24M | $81.07M | $213.89M | $214.68M |
| Income tax | -$47.03M | -$11.29M | $13.33M | $33.34M | $45.60M |
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M | $169.07M |
| EBITDA | -$448.57M | $70.81M | $152.43M | $279.02M | $236.63M |
| EPS (basic) | -6.74 | -0.09 | 0.85 | 2.18 | 2.00 |
| EPS (diluted) | -6.74 | -0.09 | 0.84 | 2.16 | 1.98 |
| Weighted avg. shares (diluted) | 76.67M | 77.01M | 80.34M | 83.52M | 85.48M |
| Balance sheet | |||||
| Cash & equivalents | $235.05M | $246.38M | $276.40M | $456.66M | $513.45M |
| Short-term investments | $28.69M | $27.19M | $32.69M | $0 | — |
| Receivables | $278.85M | $272.37M | $259.33M | $263.46M | $231.83M |
| Inventory | $492.74M | $429.09M | $389.61M | $324.58M | $317.39M |
| Current assets | $1.16B | $1.08B | $1.06B | $1.16B | $1.15B |
| PP&E, net | $444.33M | $405.72M | $340.20M | $311.30M | $311.70M |
| Goodwill | $615.16M | $1.10B | $1.06B | $1.04B | $1.01B |
| Intangibles | $1.13B | $1.21B | $1.07B | $1.13B | $1.15B |
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | $3.78B |
| Current liabilities | $455.98M | $922.13M | $306.98M | $320.91M | $340.02M |
| Long-term debt | $726.56M | $760.47M | $775.00M | $775.00M | $843.75M |
| Total debt | $726.56M | $760.47M | $775.00M | $775.00M | $843.75M |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | $2.10B |
| Shareholders' equity | $1.04B | $1.55B | $1.59B | $1.80B | $1.68B |
| Net debt | $491.51M | $514.09M | $498.60M | $318.34M | $330.30M |
| Cash flow statement | |||||
| Operating cash flow | $50.38M | $129.38M | $139.96M | $264.47M | $312.43M |
| Capital expenditure | $81.44M | $104.42M | $66.86M | $42.34M | $48.02M |
| Free cash flow | -$31.05M | $24.96M | $73.09M | $222.13M | $264.40M |
| Investing cash flow | -$108.06M | -$390.81M | -$94.18M | -$58.58M | -$161.44M |
| Financing cash flow | $28.34M | $237.86M | -$229.93M | -$251.95M | -$98.23M |
| Depreciation & amortization | $44.80M | $42.40M | $40.90M | $40.10M | $39.40M |
| Stock-based compensation | $18.58M | $24.38M | $20.14M | $27.73M | $36.21M |
| Share buybacks | $221,000 | $52.47M | $275.00M | $125.00M | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.